RedHill Biopharma (RDHL) Receivables - Net (2022 - 2024)
RedHill Biopharma (RDHL) has disclosed Receivables - Net for 3 consecutive years, with $2.5 million as the latest value for Q4 2024.
- Quarterly Receivables - Net fell 2.01% to $2.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2024, down 2.01% year-over-year, with the annual reading at $2.5 million for FY2024, 2.01% down from the prior year.
- Receivables - Net for Q4 2024 was $2.5 million at RedHill Biopharma, down from $2.6 million in the prior quarter.
- The five-year high for Receivables - Net was $34.5 million in Q4 2022, with the low at $2.5 million in Q4 2024.
- Average Receivables - Net over 3 years is $13.2 million, with a median of $2.6 million recorded in 2023.
- The sharpest move saw Receivables - Net plummeted 92.49% in 2023, then decreased 2.01% in 2024.
- Over 3 years, Receivables - Net stood at $34.5 million in 2022, then tumbled by 92.49% to $2.6 million in 2023, then decreased by 2.01% to $2.5 million in 2024.
- According to Business Quant data, Receivables - Net over the past three periods came in at $2.5 million, $2.6 million, and $34.5 million for Q4 2024, Q4 2023, and Q4 2022 respectively.